{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:58:17Z","timestamp":1790888297729,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,26]],"date-time":"2027-09-26T00:00:00Z","timestamp":1821916800000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["R01HG010365"],"award-info":[{"award-number":["R01HG010365"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.gim.2026.102697","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:04:48Z","timestamp":1787760288000},"page":"102697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of BRCA1\/BRCA2 variant reclassification and recontact for hereditary breast and ovarian cancer in the United States"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9095-1672","authenticated-orcid":false,"given":"Gregory F.","family":"Guzauskas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serra","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Topper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-5685","authenticated-orcid":false,"given":"Wendy K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.gim.2026.102697_bib1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.gim.2026.102697_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2026.102697_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1089\/pop.2020.0115","article-title":"Genetic variant reinterpretation: economic and population health management challenges","volume":"24","author":"Pag\u00e1n","year":"2021","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.gim.2026.102697_bib5","article-title":"Impact of a cancer gene variant reclassification program over a 20-year period","volume":"4","author":"Esterling","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.gim.2026.102697_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.44526","article-title":"Clinical variant reclassification in hereditary disease genetic testing","volume":"7","author":"Kobayashi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.gim.2026.102697_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100801","article-title":"Practical considerations for reinterpretation of individual genetic variants","volume":"25","author":"Appelbaum","year":"2023","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.gim.2026.102697_bib8","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.37765\/ajmc.2021.88763","article-title":"Reimbursement for genetic variant reinterpretation: five questions payers should ask","volume":"27","author":"Veenstra","year":"2021","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1016\/j.gim.2026.102697_bib9","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","article-title":"Prevalence of variant reclassification following hereditary cancer genetic testing","volume":"320","author":"Mersch","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.gim.2026.102697_bib10","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/s41436-019-0526-x","article-title":"Correction: variant classification changes over time in BRCA1 and BRCA2","volume":"21","author":"Mighton","year":"2019","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2026.102697_bib11","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cam4.5202","article-title":"A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes","volume":"12","author":"Makhnoon","year":"2023","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.gim.2026.102697_bib12","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/cam4.4541","article-title":"Racial and ethnic variation in multigene panel testing in a cohort of BRCA1\/2-negative individuals who had genetic testing in a large urban comprehensive cancer center","volume":"11","author":"Tatineni","year":"2022","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.gim.2026.102697_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M22-0846","article-title":"Population genomic screening for three common hereditary conditions: a cost-effectiveness analysis","volume":"176","author":"Guzauskas","year":"2023","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.gim.2026.102697_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22874","article-title":"Cost-effectiveness of population-wide genomic screening for hereditary breast and ovarian cancer in the United States","volume":"3","author":"Guzauskas","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gim.2026.102697_bib15","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"issue":"1","key":"10.1016\/j.gim.2026.102697_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"22","key":"10.1016\/j.gim.2026.102697_bib17","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1001\/jama.2024.5534","article-title":"Screening for breast cancer: US Preventive Services Task Force recommendation statement","volume":"331","author":"Nicholson","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gim.2026.102697_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10897-016-9995-0","article-title":"Psychosocial and clinical factors associated with family communication of cancer genetic test results among women diagnosed with breast cancer at a young age","volume":"26","author":"Elrick","year":"2017","journal-title":"J Genet Couns"},{"issue":"5","key":"10.1016\/j.gim.2026.102697_bib20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1377\/hlthaff.2017.1630","article-title":"Delivery of cascade screening for hereditary conditions: a scoping review of the literature","volume":"37","author":"Roberts","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"12","key":"10.1016\/j.gim.2026.102697_bib21","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast cancer","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.gim.2026.102697_bib22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/jnci\/djx265","article-title":"Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women","volume":"110","author":"Manchanda","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.gim.2026.102697_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gim.2026.102697_bib24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/erp.10.65","article-title":"Health-state utility values in breast cancer","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.gim.2026.102697_bib25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jval.2017.01.006","article-title":"A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer","volume":"20","author":"Li","year":"2017","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.gim.2026.102697_bib28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.gim.2026.102697_bib29","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.gim.2022.06.002","article-title":"Challenges of variant reinterpretation: opinions of stakeholders and need for guidelines","volume":"24","author":"Berger","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2026.102697_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1455509","article-title":"Reclassification of variants of uncertain significance by race, ethnicity, and ancestry for patients at risk for breast cancer","volume":"15","author":"Pleasant","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.gim.2026.102697_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajhg.2020.05.005","article-title":"Clinical genetics lacks standard definitions and protocols for the collection and use of diversity measures","volume":"107","author":"Popejoy","year":"2020","journal-title":"Am J Hum Genet"},{"issue":"11","key":"10.1016\/j.gim.2026.102697_bib32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/humu.23644","article-title":"The clinical imperative for inclusivity: race, ethnicity, and ancestry (REA) in genomics","volume":"39","author":"Popejoy","year":"2018","journal-title":"Hum Mutat"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360026010154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360026010154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:27:56Z","timestamp":1790886476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360026010154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1098360026010154"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2026.102697","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of BRCA1\/BRCA2 variant reclassification and recontact for hereditary breast and ovarian cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2026.102697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"102697"}}